Parkinson's Disease - KOL Insight

Description

Based on insights from interviews with key opinion leaders, this report provides an in depth look into the current and future treatment landscape for Parkinson's Disease, focusing on the efficacy, challenges, and potential of existing and pipeline therapies. Gain a comprehensive understanding of treatment algorithms, unmet needs, and the evolving therapeutic strategies, including the role of levodopa, emerging therapies like GLP-1 agonists, and innovative brain infusion techniques.

Key questions answered:

What treatments currently form the backbone of Parkinson's Disease therapy?
What are the advantages and disadvantages of these treatments?
What are the current unmet needs and challenges in treating Parkinson's Disease?
Which products are currently in the development pipeline, and what impact are they expected to have on treatment pathways?
Do any of the current pipeline therapies address unmet treatment needs?
How is the Parkinson's Disease treatment landscape expected to evolve over the next three to five years?

Key brands covered in this report:

Alpha-synuclein inhibitors (e.g. cinpanemab, ENT-01, ION464, prasinezumab, UCB0599)
Buntanetap ((+)(3aR)phenserine)
Cell/gene therapies and various other early-stage MOAs
Comtan (entacapone)
DNL151
Dostinex (cabergoline)
Duopa (levodopa/carbidopa intraduodenal)
IPX203 (carbidopa/levodopa)
Mesdopetam
Ongentys (opicapone)
P2B-001 (pramipexole/rasagiline)
PRODUODOPA/VYALEV (foscarbidopa/foslevadopa)
Repurposed drugs (e.g. nilotinib, GLP-1 agonists (exenatide sustained-release, liraglutide, lixisenatide NLY01), etc.)
Requip franchise (ropinirole/ER)
Rytary (levodopa/carbidopa ER)
Stalevo (levodopa/carbidopa/entacapone)

Companies:

AbbVie
Novartis
Teva
Lilly
Lundbeck
Roche
GS
K Sanofi
UCB
Pfizer
Merck Sharp & Dohme
Merck & Co.
Biogen
BIAL
Sunovion
Eisai
Bayer
Grifols
Boehringer Ingelheim
Bausch Health
Ipsen
Orion Pharma
Zambon
Amneal Pharmaceuticals
Ionis

Mitsubishi Tanabe
Yuhan
Prevail Therapeutics
Pharma Two B
Perrigo
Peptron
Neuropore Therapies
NeuroDerm
Neuraly
Luye Pharma Group
LobSor Pharmaceuticals
Living Cell Technologies
Kyowa Kirin
Hisamitsu Pharmaceutical
D&D Pharmatech
Cerevel Therapeutics
Brain Neurotherapy Bio
AskBio
AOP Orphan Pharmaceuticals
Alkahest
Denali Therapeutics
Annovis Bio
STADA Arzneimittel
Agyany Pharma

Executive summary

This report is based on the leading insights from interviews with six key opinion leaders (KOLs) from the USA and six from Europe. FirstWord's research and analysis for Therapy Trends KOL Insight: Parkinson's Disease identified the following major findings:

Current and future treatment algorithm

Research objectives

Current treatment practice and unmet needs in Parkinson's disease

Key insights summary
- First-line treatment for PD is usually either levodopa, a dopamine agonist or a MAO-B inhibitor, depending on age, activity, severity of symptoms and formulation convenience

New directions in Parkinson's disease therapy

Key insights summary
- Promising new directions in PD treatment include subcutaneous levodopa, LRRK2 targeting, repurposed GLP-1 agonists and brain infusion of dopamine

Approved therapies

Dopamine agonists
- Key insights summary
Fixed-dose combination (FDC) agents
- Key insights summary
MAO-B inhibitors
- Key insights summary
COMT inhibitors
- Key insights summary
Other agents
- Key insights summary

Pipeline therapies

Dopamine agonists
- Aplindore (DAB 452; Seelos Therapeutics)
- Tavapadon (AbbVie/Cerevel Therapeutics)
FDC therapies
- Levodopa + carbidopa subcutaneous infusions
- ND0612 (levodopa + carbidopa subcutaneous infusion; NeuroDerm/Mitsubishi Tanabe Pharma)
- P2B001 (pramipexole + rasagiline; Pharma Two B)
Other modes of action
- Nabilone FDT (AOP Orphan Pharmaceuticals)
- Mesdopetam (Integrative Research Laboratories)
- Buntanetap (R-phenserine/Posiphen; Annovis Bio)
Early-phase drug candidates
- Alpha-synuclein inhibitors
- UCB0599 (UCB)
- PRX002 (prasinezumab; Roche)
- ENT-01 (kenterin; Enterin)
- ION464 (Ionis Pharma/Biogen)
- Radotinib (Il-Yang Pharm. Co.)
- Repurposed drugs
- Cell transplantation therapies
- Viral gene delivery approaches
Other mechanisms of action/pipeline candidates
- Key insights summary

Future treatment paradigm

Key insights summary
- Disease modification remains elusive in PD, but the next five years should see better and earlier symptomatic treatment, together with more attention to non-motor symptoms

Appendix

KOL details
- KOLs from the USA
- KOLs from Europe